AstraZeneca shares dropped over seven percent after merger talks leaked
Britain's biggest drugmaker is discussing a massive combination with its American counterpart to build a global pharmaceutical titan. Pascal Soriot leads the British firm, which is valued at nearly £196bn before the news emerged. Investors reacted negatively on Monday, sending shares down by more than 7% in early trading.
Lost in this story? That's the point of BriefTea.
Open it in the app and tap Learn from this — the Knowledge Galaxy turns the story into a map of everything it assumes you know, one tap at a time. Free, no ads, no paywall.
Get BriefTea on the App Store